Foghorn Non Operating Income Net Other from 2010 to 2025

FHTX Stock  USD 4.34  0.36  9.05%   
Foghorn Therapeutics Non Operating Income Net Other yearly trend continues to be fairly stable with very little volatility. Non Operating Income Net Other is likely to outpace its year average in 2025. During the period from 2010 to 2025, Foghorn Therapeutics Non Operating Income Net Other regression line of annual values had r-squared of  0.60 and arithmetic mean of  2,818,823. View All Fundamentals
 
Non Operating Income Net Other  
First Reported
2010-12-31
Previous Quarter
9.5 M
Current Value
10 M
Quarterly Volatility
3.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 12.8 M, Interest Income of 12.8 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 8.66, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Foghorn Therapeutics Correlation against competitors.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Latest Foghorn Therapeutics' Non Operating Income Net Other Growth Pattern

Below is the plot of the Non Operating Income Net Other of Foghorn Therapeutics over the last few years. It is Foghorn Therapeutics' Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Non Operating Income Net Other10 Years Trend
Slightly volatile
   Non Operating Income Net Other   
       Timeline  

Foghorn Non Operating Income Net Other Regression Statistics

Arithmetic Mean2,818,823
Geometric Mean1,391,127
Coefficient Of Variation131.44
Mean Deviation3,086,984
Median710,000
Standard Deviation3,705,190
Sample Variance13.7T
Range9.3M
R-Value0.77
Mean Square Error6T
R-Squared0.60
Significance0.0005
Slope600,325
Total Sum of Squares205.9T

Foghorn Non Operating Income Net Other History

202510 M
20249.5 M
20228.3 M
20211.3 M

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Operating Income Net Other9.5 M10 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.